Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.

Szczegóły
Abstrakt

Tytuł:: Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.
Autorzy:: Weber J; St Mary's Hospital Medical School, London, UK.
Cheinsong-Popov R
Callow D
Adams S
Patou G
Hodgkin K
Martin S
Gotch F
Kingsman A
Źródło:: Vaccine [Vaccine] 1995 Jun; Vol. 13 (9), pp. 831-4.
Typ publikacji:: Clinical Trial; Clinical Trial, Phase I; Journal Article
Język:: English
Imprint Name(s):: Publication: Amsterdam, The Netherlands : Elsevier Science
Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
MeSH Terms:: Viral Proteins*
AIDS Vaccines/*immunology
Gene Products, gag/*immunology
HIV/*immunology
HIV Antigens/*immunology
HIV Core Protein p24/*immunology
HIV Infections/*prevention & control
AIDS Vaccines/genetics ; AIDS Vaccines/therapeutic use ; Adult ; Blotting, Western ; Enzyme-Linked Immunosorbent Assay ; HIV Antibodies/biosynthesis ; HIV Core Protein p24/genetics ; HIV Core Protein p24/therapeutic use ; Humans ; Male ; Middle Aged ; Reference Values ; Saccharomyces cerevisiae/genetics ; T-Lymphocytes, Cytotoxic/cytology ; T-Lymphocytes, Cytotoxic/immunology ; Vaccines, Synthetic/genetics ; Vaccines, Synthetic/immunology ; Vaccines, Synthetic/therapeutic use ; gag Gene Products, Human Immunodeficiency Virus
Substance Nomenclature:: 0 (AIDS Vaccines)
0 (Gene Products, gag)
0 (HIV Antibodies)
0 (HIV Antigens)
0 (HIV Core Protein p24)
0 (Vaccines, Synthetic)
0 (Viral Proteins)
0 (gag Gene Products, Human Immunodeficiency Virus)
0 (p17 protein, Human Immunodeficiency Virus Type 1)
0 (p24-VLP vaccine)
Entry Date(s):: Date Created: 19950601 Date Completed: 19951130 Latest Revision: 20190728
Update Code:: 20240104
DOI:: 10.1016/0264-410x(94)00061-q
PMID:: 7483805
: Czasopismo naukowe

Full Text Finder

In this Phase I study, immunisation with the yeast-derived p24 virus-like particles Ty p24-VLP (3 x 100 or 3 x 500 micrograms subcutaneously) in 16 healthy male subjects elicited p24 antibody responses in 4 of 16 (25%) subjects. After a fourth, intramuscular, immunisation (500 micrograms), p24 antibody responses were detected in 11 of 15 (70%) subjects. In addition to p24 antibody responses, T cell proliferative responses were also observed, although no HLA restricted p24-specific cytotoxic T cell responses were detected. The results demonstrate that Ty p24-VLP is immunogenic and well-tolerated in healthy male subjects.

Informacja